{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:47:34Z","timestamp":1788922054662,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtocrr.2024.100735","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:19:44Z","timestamp":1729041584000},"page":"100735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment"],"prefix":"10.1016","volume":"5","author":[{"given":"Sabine","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Holer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gysel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira-Lee","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Frehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Cardoso Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Britschgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannis","family":"Metaxas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dieter","family":"Janthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Allemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Von der M\u00fchll-Schill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia A.","family":"Mauti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2024.100735_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2024.100735_bib2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib3","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A\u00a0systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir Med"},{"key":"10.1016\/j.jtocrr.2024.100735_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101432","article-title":"Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): a randomised, phase 2 trial","volume":"48","author":"Fennell","year":"2022","journal-title":"EClinicalmedicine"},{"key":"10.1016\/j.jtocrr.2024.100735_bib5","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib7","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.jtocrr.2024.100735_bib10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib11","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1002\/cam4.5915","article-title":"Epidemiological, therapeutic, and survival trends in malignant pleural mesothelioma: a review of the National Cancer Database","volume":"12","author":"Bou-Samra","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtocrr.2024.100735_bib12","first-page":"516","article-title":"Inflammation in malignant mesothelioma - friend or foe?","volume":"1","author":"Linton","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.jtocrr.2024.100735_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1121557","article-title":"Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress","volume":"14","author":"Perrino","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1269029","article-title":"PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma","volume":"13","author":"Avil\u00e9s-Salas","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib15","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","article-title":"Real-world evidence in oncology: opportunities and limitations","volume":"25","author":"Di Maio","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtocrr.2024.100735_bib16","article-title":"A\u00a0real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern","volume":"3","author":"Kerrigan","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtocrr.2024.100735_bib17","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107440","article-title":"Nivolumab and ipilimumab in the real-world setting in patients with mesothelioma","volume":"187","author":"Dumoulin","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2024.100735_bib19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jtho.2023.11.014","article-title":"Brief report: real-world toxicity and survival of combination immunotherapy in pleural mesothelioma-RIOMeso","volume":"19","author":"McNamee","year":"2024","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib20","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1200\/JCO.2024.42.16_suppl.8085","article-title":"Efficacy of nivolumab\/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting","volume":"42","author":"Shah","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107866","article-title":"Real-World efficacy and safety of combination nivolumab plus ipilimumab for untreated, unresectable, pleural mesothelioma: the Meso-Immune (GFPC 04\u20132021) trial","volume":"194","author":"Bylicki","year":"2024","journal-title":"Lung Cancer"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2024.100735_bib22","article-title":"Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (\u2265 70 years) patients with advanced non\u2013small cell lung cancer (Energy-GFPC 06-2015 study)","volume":"40","author":"Lena","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib23","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin cisplatin pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtocrr.2024.100735_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and Platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2024.100735_bib25","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21037\/jtd.2016.07.55","article-title":"Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma","volume":"8","author":"Sandri","year":"2016","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtocrr.2024.100735_bib26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jtho.2023.02.003","article-title":"Brief report: Canadian cancer trials group IND.227: a phase 2 randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)","volume":"18","author":"Piccirillo","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2024.100735_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8002","article-title":"BEAT-meso: a randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)\u2014results from the ETOP 13-18 trial","volume":"42","author":"Popat","year":"2024","journal-title":"J\u00a0Clin Oncol"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432400105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432400105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:34:15Z","timestamp":1733618055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266636432400105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S266636432400105X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100735","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100735"}}